Asep Medical Holdings Inc · CSE:ASEP
Asep Medical — Investor Presentation (September 2025)
29 slides from Asep Medical's investor presentation, September 2025
Slide 1: Transforming the Fight Against Sepsis
TRANSFORMING THE FIGHT AGAINST SEPSIS
Slide 2: Robert Hancock, Founder, CEO
Robert Hancock OC, OBC, FRSC Founder, CEO Leading microbiologist and entrepreneurial scientist at University of British Columbia, Canada for 40 years. Named 2nd best Microbiologist in world in 20241 Top 0.05% of medical scientists worldwide2 Major role in translating University discoveries into new
Slide 3: Sepsis: One of the Most Serious Problems
SEPSIS: ONE OF THE MOST SERIOUS PROBLEMS https://www.worldsepsisday.org/sepsisfacts 49 million sepsis cases #1 cause of death 80% in hospitals of deaths could be Worldwide per year prevented if treated in time #1 cause of 11 million deaths hospital per year readmissions 100% of all pandemic-related
Slide 4: Sepset Has the Solution
SEPSET HAS THE SOLUTION A better technology For use in the for sepsis diagnosis: emergency room SepsetER is a SepsetER gene-based assay and early ICU is the answer invented by Dr. Hancock and his team and Easy to operate patented by Asep Medical in the US, Results in ~ 1 hour Europe & Australia The
Slide 5: SepsetER Dramatically Shortens the Time to Diagnosis of Sepsis
SepsetER, DRAMATICALLY SHORTENS THE TIME TO DIAGNOSIS OF SEPSIS → EARLIER TREATMENT Ave. 13 hours for definitive diagnosis Symptoms are Poor Patient Clinician Patient Presents Non-specific and Outcomes, Suspects Sepsis – to ER with Illness Treatment is ICU Admission Blood Collected 7.6% Delayed 22%
Slide 6: Excellent Performance of SepsetER on Clinical Samples
EXCELLENT PERFORMANCE OF SepsetER ON CLINICAL SAMPLES1 Sensitivity as high as 94%; Accuracy as high as 87% Dataset Patients AUC SENS ACC Hancock ICU (2 Cities) 176 0.90 92% 87% Severe COVID-19 (Quebec) 359 0.85 85% 79% Hancock ER (4 Countries) 338 0.69 70% 65% SepsetER PCR test (Toronto) 248 0.88 94
Slide 7: Nature Communications Publication on Sepset
nature communications 8 Sepset”™ Article https://doi.org/10.1038/s41467-025-59227-x A machine learning and centrifugal microfluidics platform for bedside prediction of sepsis Received: 11 October 2024 Lidija Malic!?:*° | Peter G. Y. Zhang*"°, Pamela J. Plant®"°, Liviu Clime', Christina Nassif", Dill
Slide 8: SepsetER Outperforms Other Signatures on Clinical Samples
SepsetER OUTPERFORMS OTHER SIGNATURES ON CLINICAL SAMPLES * Mean AUC Davenport Cancer Negative Signature N=3178 ICU N=371 Control N=1755 SepsetER n6 0.88 0.83 0.50 SeptiCyte Rapid n2 0.61 0.60 0.39 * Company analysis based on SepsetER and published SeptiCyte signature Inflammatix Triverity Number in
Slide 9: A.I. Drove Sepset Discoveries
A.I. DROVE SEPSET DISCOVERIES Diagnosing sepsis in a timely fashion to speed the medical response (SepsetER) 572 patients → Blood RNA-Seq 11,000 genes expressed AMPLIFICATION PLOT SepsetER signature accurately LASSO diagnoses sepsis AI and organ failure • Signature Gene 1 in 1 hour • • Signature Gen
Slide 10: SepsetER Commercialization Path in North America
SepsetER, COMMERCIALIZATION PATH IN NORTH AMERICA Test accurately assesses high risk of sepsis within 24 hours in 9 of 10 patients (Based on clinical data from >3,000 patients; >500 using test kit parameters). Q3 2024 Q1 2025 Q4 2025 Q2 2026 Q3 2026 Q4 2026 Test kit methods Start of registration Cle
Slide 11: Sepset Products Address Billion Dollar Markets
SEPSET PRODUCTS ADDRESS BILLION DOLLAR MARKETS $1.3B Global Estimated cost savings Sepsis in the USA, per year: Diagnostic Market >$3.0 million by 2030; per hospital CAGR: 9.7% >$16.6 billion https://www.grandviewresearch.com/industry- analysis/sepsis-diagnostics-market in total A massive business o
Slide 12: Accelerated Product Adoption and Distribution
ACCELERATED PRODUCT ADOPTION AND DISTRIBUTION Goal. Better clinical solutions for sepsis, improved patient outcomes & reduced medical industry costs, while generating high returns on investor’s capital. Bring SepsetER to market in USA, India and China in 2026. Maintain aggressive business develop
Slide 13: Investment Highlights
INVESTMENT HIGHLIGHTS Novel Technologies Large Addressable Global Markets Extensive Intellectual Property In the early diagnosis of sepsis With No efficient clinical solutions and underlying endotypes (unmet medical needs) Portfolio in Diagnostics Experienced Optimized Business Model Seeking Funding
Slide 14: Sepset
Sepset”™
Slide 15: Transforming the Fight Against Antimicrobial Resistance (AMR)
TRANSFORMING THE FIGHT AGAINST ANTIMICROBIAL Named 2nd best Microbiologist in RESISTANCE (AMR) the world in 2023 by Research.com https://research.com/ scientists-rankings/ microbiology
Slide 16: Our Therapeutics Address Biofilms
Our Therapeutics address Biofilms: A distinct and important issue in AMR Proprietary peptide Biofilm killed Biofilm technology directly Human Skin Model Skin damage reversed addresses the ineffectiveness of current treatment options for biofilm- infections by targeting and suppressing biofilm growth
Slide 17: Bacterial Biofilms – A Major Unmet Medical Need
Bacterial biofilms and biofilm associated infections – A Major Unmet Medical Need • Adaptively multidrug resistance (10-1000 X) to conventional antibiotics • Clinically relevant - >65% of all bacterial infections • Estimated cost to global healthcare of $368 billion* • No biofilm specific therapies
Slide 18: A.I. Drives ABT Discoveries
A.I. DRIVES ABT DISCOVERIES The problem: Finding the most active peptides R R R A V Neural Networks Thousands of A V A V R I VAE Autoencoder R R antibiofilm I I V K ExAI V V I V W peptides I R I R R A L made A L A L R R R 50 - 0 0.25 2 16 Peptide Concentration (µM)
Slide 19: Therapeutic Target 1: Oral Biofilms
Therapeutic Target 1: Oral Biofilms • Oral plaque is a polymicrobial biofilm that forms around teeth in the oral cavity • Typically removed mechanically • Also associated with dentures and dental implants • Can contribute to infections in the oral cavity which cannot be treated with antibiotics • Gl
Slide 20: ABT Peptides Destroy Complex Oral Biofilms on Hydroxyapatite
ABT Peptides destroy Complex Oral Biofilms on Hydroxyapatite Confocal Microscopy Peptides work rapidly & synergize with EDTA & Scanning Electron Microscopy Chlorhexidine → No peptide CHX + ABT18 CHX + ABT5 10 µg/ml ABT18 Red = Wang, Z, et al. 2015. PLoS One 10, e0132512. Saline ABT18 Low mag Dead Zh
Slide 21: Short-term Treatment with Peptide Superior to Chlorhexidine
Short-term treatment with peptide is superior to oral disinfectant Chlorhexidine ** ABT5 CHX+ABT5
Slide 22: Peptide Superior to Listerine and Paroex Gum
Peptide is superior to Listerine and Paroex Gum (0.12% Chlorhexidine gluconate) ABT5 ABT5 Dynamic antibiofilm effect on 1-week-old biofilm from a donor grown on dental materials. The proportion of dead bacterial cells after 7 days of different treatments (water, Paroex Gum, Listerine (LIS), CHX and
Slide 23: In Human Volunteers, Peptide + Chlorhexidine Superior as Oral Rinse
In Human Volunteers, Peptide + Chlorhexidine Combination is superior as an Oral Rinse ABT5 + CHX ABT5 Asep5 CHX Water ABT5 + CHX Confocal ABT5 microscopy of 0.2% CHX biofilms grown in Water the oral cavity of three human volunteers. Biofilms were treated with peptide (ABT5), Chlorhexidine (CHX), or
Slide 24: ABT Peptides Address Many Biofilm Associated Infections
ABT peptides address many bacterial biofilm associated infections Infected control Targets Treated Next: Infected Wounds (Global Wound Care Market $20B, CAGR: 4.1%). Serious wound infections often become Broad Spectrum contaminated by bacterial biofilms → prevent healing. Asep Activity, e.g. vs. pep
Slide 25: Peptide Use in Oral Rinses
Peptide use in Oral Rinses • Peptides were very effective against oral biofilms when used alone or combined with chlorhexidine and can be used as an oral rinse. • Peptides had a 3-fold stronger antibacterial effect than traditional oral rinses and killed significantly more biofilm microbes. • Peptid
Slide 26: Other Indications
Other Indications ABT has data for each of these indications Prevention of … Caries Periodontal Infections Endodontic Infections Dental Implant Infections Dental Pulp Regeneration Traumas Anatomical pathways (e.g. Invagination) etc…
Slide 27: Proceeds Will Be Used to Develop the Initial Therapeutic Product
Proceeds will be used to develop the Initial Therapeutic Product 2014 Therapeutics Development 2026 CAD $17 M of non-dilutive and dilutive $10 M funding needed for each of oral irrigant funding and wound indications • ABT peptides destroy oral biofilms; oral • Finalize partnerships for commercializa
Slide 28: Asep Intellectual Property
Asep Intellectual Property Therapeutics 3 PATENT FAMILIES, 18 FILED PATENTS 8 AWARDED Small Cationic Antimicrobial Peptides 8 Patents in US, Europe, Australia, etc. Cationic peptides with immunomodulatory, and/or anti-biofilm activity National entry process Cationic Peptides with broad Spectrum Anti
Slide 29: Business Model – Global Market Opportunities, e.g. Oral Health
Business Model – Global Market Opportunities, e.g. Oral Health Business model is based on partnerships that will generate studies to support regulatory registrations where needed and go-to-market strategies for the Oral Rinse on a global basis. 1. An initial "Safety Study" by Dr. Ya Shen, UBC School
Asep Medical Holdings — Investor Presentation (September 2025) on 6ix